Study of INBRX-109 in Conventional Chondrosarcoma — ChonDRAgon

Conventional Chondrosarcoma Clinical Trial

Official title:
A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma

Status Recruiting

Clinical Trial Summary

Randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients.

Clinical Trial Description

This is a randomized, blinded, placebo-controlled, Phase 2 study of INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. INBRX-109 is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04950075
Study type	Interventional
Source	Inhibrx, Inc.
Contact	Study Director, -Inhibrx
Phone	858-500-7833
Email	clinicaltrials@inhibrx.com
Status	Recruiting
Phase	Phase 2
Start date	September 23, 2021
Completion date	June 2025

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02821507` - Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma	Phase 2
	Completed	`NCT01310816` - A Safety and Efficacy Study of Patients With Metastatic or Locally Advanced (Unresectable) Chondrosarcoma	Phase 2